Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,085 Million (Mid Cap)
52.00
NA
0.00%
0.29
11.63%
5.90
Revenue and Profits:
Net Sales:
183 Million
(Quarterly Results - Sep 2025)
Net Profit:
38 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.39%
0%
-17.39%
6 Months
-12.26%
0%
-12.26%
1 Year
91.85%
0%
91.85%
2 Years
60.91%
0%
60.91%
3 Years
94.62%
0%
94.62%
4 Years
64.05%
0%
64.05%
5 Years
0%
0%
0.0%
Cheng Du Sheng Nuo Biotec Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.33%
EBIT Growth (5y)
70.94%
EBIT to Interest (avg)
6.55
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
0.37
Tax Ratio
17.66%
Dividend Payout Ratio
22.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.26%
ROE (avg)
9.15%
Valuation key factors
Factor
Value
P/E Ratio
52
Industry P/E
Price to Book Value
6.10
EV to EBIT
42.84
EV to EBITDA
33.29
EV to Capital Employed
5.00
EV to Sales
10.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.68%
ROE (Latest)
11.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
182.50
138.90
31.39%
Operating Profit (PBDIT) excl Other Income
47.50
54.00
-12.04%
Interest
5.20
3.70
40.54%
Exceptional Items
0.00
0.00
Consolidate Net Profit
38.10
35.10
8.55%
Operating Profit Margin (Excl OI)
260.30%
317.40%
-5.71%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 31.39% vs 18.31% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 8.55% vs 140.41% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
454.40
431.00
5.43%
Operating Profit (PBDIT) excl Other Income
101.10
105.20
-3.90%
Interest
12.00
9.30
29.03%
Exceptional Items
0.30
0.30
Consolidate Net Profit
49.80
70.30
-29.16%
Operating Profit Margin (Excl OI)
144.20%
176.50%
-3.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 5.43% vs 10.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -29.16% vs 8.99% in Dec 2023
About Cheng Du Sheng Nuo Biotec Co., Ltd. 
Cheng Du Sheng Nuo Biotec Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






